Zyversa Therapeutics Inc. (ZVSA)
OTC PINK OTC PINK Primary Summary
Zyversa Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| FG Fabian Guerra Guerra Advisors Inc. | 7 | $1 | $1.12 | $0.12 | 12% |
Zyversa Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EA Ed Arce WestPark Capital | -13,873.08 | $107,516.39 | $2,219.69 | $105,296.7 | 97.94% |
Zyversa Therapeutics Inc. (ZVSA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zyversa Therapeutics Inc. ever had a stock split?
Zyversa Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stephen C. Glover CEO | OTC PINK Exchange | 98987D201 CUSIP |
| US Country | 7 Employees | - Last Dividend | 26 Apr 2024 Last Split | - IPO Date |
Overview
Zyversa Therapeutics Inc. is a clinical-stage pharmaceutical company with a sharp focus on fulfilling the unmet medical needs in the realm of inflammatory and renal diseases. Through the development of promising drug candidates, Zyversa aims to significantly impact areas where current medical solutions fall short. Operating within the biotech sector, the company carves out a niche for itself by specializing in immunology and nephrology, two fields that not only demand innovative treatments but also represent areas of significant overlap in patient care management. Zyversa's dedication to pioneering therapeutic advances is embodied in its strategic collaborations with research institutions, combining its internal scientific expertise with external innovation to push the boundaries of what's currently achievable in healthcare. Positioned at the intersection of scientific discovery and urgent medical necessity, Zyversa stands as a beacon for progress in treating conditions that have long challenged the healthcare community.
Products and Services
Zyversa Therapeutics Inc. focuses on developing a range of drug candidates aimed at addressing the challenges faced by patients with inflammatory and renal diseases. Each area of focus is carefully chosen based on the unmet needs in the healthcare sector, particularly in chronic kidney disease and various inflammatory conditions.
- Chronic Kidney Disease Treatments
- Inflammatory Condition Therapies
Targeting a condition that affects a significant portion of the global population, Zyversa is in the process of advancing drug candidates designed to combat the progression of chronic kidney disease. These treatments revolve around the idea of modulating the immune system and inflammatory responses, aiming to offer patients a chance at a better quality of life and potentially slowing the disease's progression.
Understanding the critical need for innovative treatments in the battle against diseases rooted in inflammation, Zyversa is dedicated to the development of therapies that address this core issue. By focusing on the immune system's role in conditions such as autoimmune diseases, the company strives to create effective treatments that not only relieve symptoms but also target the underlying causes of inflammation, thereby offering a holistic approach to disease management.
